Evidence map›Paper›PMID 42132594›Full record

ArticleJournal of radiation research2026

Comparison of percutaneous and transarterial fiducial marker placement before proton therapy for pancreatic cancer.

Jumpei Shoji, Kengo Ohta, Kazushi Suzuki, Akihiro Horibe, Motoki Hatano, Kazuma Murai, Koichiro Nakajima, Hiromitsu Iwata, Hiroyuki Ogino, Akio Hiwatashi

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of radiation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jumpei ShojiNagoya City University West Medical Center, Diagnostic Radiology Department, 462-8508, 1-1-1, Hirate-cho, kita-ku, Nagoya, Japan.
Kengo OhtaRadiology Department, Nagoya City University Graduate School of Medical Sciences, 467-8601, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Japan.ORCID 0000-0003-1509-6730
Kazushi SuzukiRadiology Department, Nagoya City University Graduate School of Medical Sciences, 467-8601, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Japan.
Akihiro HoribeNagoya City University West Medical Center, Diagnostic Radiology Department, 462-8508, 1-1-1, Hirate-cho, kita-ku, Nagoya, Japan.
Motoki HatanoDiagnostic Radiology Department, Midori Municipal Hospital, 458-0037, 1-77, Siomigaoka, Midori-ku, Nagoya, Japan.
Kazuma MuraiNagoya City University West Medical Center, Diagnostic Radiology Department, 462-8508, 1-1-1, Hirate-cho, kita-ku, Nagoya, Japan.
Koichiro NakajimaNagoya Proton Therapy Center, Radiation Oncology Department, Nagoya City University West Medical Center, 462-8508, 1-1-1, Hirate-cho, kita-ku, Nagoya, Japan.ORCID 0000-0002-2306-7836
Hiromitsu IwataNagoya Proton Therapy Center, Radiation Oncology Department, Nagoya City University West Medical Center, 462-8508, 1-1-1, Hirate-cho, kita-ku, Nagoya, Japan.ORCID 0000-0001-9809-9800
Hiroyuki OginoNagoya Proton Therapy Center, Radiation Oncology Department, Nagoya City University West Medical Center, 462-8508, 1-1-1, Hirate-cho, kita-ku, Nagoya, Japan.ORCID 0000-0002-6035-7402
Akio HiwatashiRadiology Department, Nagoya City University Graduate School of Medical Sciences, 467-8601, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Japan.ORCID 0000-0001-5400-5083

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to evaluate the feasibility and safety of percutaneous fiducial marker placement using a 25G needle compared with transarterial placement before proton therapy for pancreatic cancer. MATERIALS AND

methodsPatients who underwent fiducial marker placement from 2013 to 2023 were retrospectively reviewed. For percutaneous placement, a 25G needle was used to place markers in or around the tumor under computed tomography (CT) guidance. For transarterial placement, a metal coil was placed as a fiducial marker in a blood vessel near the tumor using a microcatheter. Technical success was defined as the reliable use of the placed fiducial marker throughout the entire proton therapy course. Major complications were defined as grade 3 or higher. Each outcome was compared using Fisher's exact test or the Mann-Whitney U test.

resultsForty-nine and 60 patients underwent percutaneous and transarterial fiducial marker placement, respectively. The technical success rates were 89.8 and 90.0% for percutaneous and transarterial placement, respectively, with no statistically significant difference between them (P > 0.99). There were no major complications in either case. The median procedure time for percutaneous placement was significantly shorter than that for transarterial placement (3.3 vs 40.0 min; P < 0.001). The median distance between the marker and the tumor was shorter with percutaneous placement than with transarterial placement (0.0 vs 10.0 mm; P = 0.005).

conclusionPercutaneous placement of fiducial markers for pancreatic cancer proton therapy using a 25G needle could be performed faster than transarterial placement with a high success rate.

Indexed as

Fiducial MarkersPancreatic NeoplasmsProton TherapyAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesTomography, X-Ray Computedfiducial markerpancreatic cancerpercutaneous placementproton therapy

Identifiers

PMID42132594
PMCPMC13400558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.